Disc Medicine Gets FDA Commissioner's National Priority Voucher for Drug Candidate

MT Newswires Live
2025/10/17

Disc Medicine (IRON) said late Thursday it has received Commissioner's National Priority Voucher, meant to expedite drug review process, from the US Food and Drug Administration for its drug candidate bitopertin.

The company is seeking an accelerated approval of bitopertin for the treatment of erythropoietic protoporphyria, a rare and potentially life-threatening disease that causes severe reactions when patients are exposed to sunlight.

The program is aimed to reduce the drug application review process to one to two months, the company added.

Shares of Disc Medicine were up 19% in after-hours trading.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10